Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca enters the BACE inhibitor Phase III stakes

This article was originally published in Scrip

Executive Summary

On the back of its recent deal with Lilly, AstraZeneca has moved its BACE inhibitor AZD3293 into Phase III testing in mild Alzheimer's disease and mild cognitive impairment, making it the second late-stage drug still in contention in this novel, but very high-risk drug class. The pipeline advance also puts the firm well on track to deliver on its Phase III pipeline promises for this year.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026671

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel